Medicyte Starts its Involvement in the Prestigious Hepatic Microfluidic Bioreactor Project


Heidelberg,  Germany,  March 22, 2011 / b3c newswire / - Medicyte has now started operational activities to provide and qualify different types of upcyte® liver cells for use in the multi-international Hepatic Microfluidic Bioreactor (HeMiBio) project. HeMiBio is an artificial liver that may be more predictive for human liver toxicity and liver metabolism of drugs than current in vitro and animal models.


Using its upcyte® technology, Medicyte has succeeded in generating quasi human primary cells (upcyte® cells). These upcyte® cells can be kept longer in culture than primary cells and even these differentiated cells can be initiated to proliferate in vitro. Most importantly, Medicyte´s upcyte® hepatocytes are functionally equivalent to human primary liver cells and can be provided in unmet high quantities of consistent quality. This makes upcyte® liver cells (hepatocytes, endothelial and stellate cells) ideal for the development of the artificial liver system “HeMiBio”.


The development of the HeMiBio is a prestigious project, involving twelve partners from seven countries. The project is coordinated by Prof. Catherine Verfaillie (Katholieke Universiteit Leuven, Belgium). Being an “in vitro artificial liver”, HeMiBio may be more predictive for human liver toxicity and liver metabolism of drugs, new chemical entities and cosmetics than currently used in vitro and animal models. Moreover, conventional chronic toxicity studies require high animal numbers that could be markedly reduced if not completely replaced by HeMiBio in the long term. HeMiBio is part of the European Research Initiative “Safety Evaluation Ultimately Replacing Animal Testing” (SEURAT) and is one of six projects, financed by European Commission’s FP7 HEALTH program and the “European Cosmetics Association” (COLIPA), that target the replacement of animal safety testing with appropriate in vitro methods. Medicyte´s efforts and expenditures for HeMiBio are fully compensated from the € 50 million fund provided by FP7 and COLIPA.


Dr. Joris Braspenning, Managing Director of Medicyte GmbH: “We are enthusiastic about working on this project together with renowned scientific institutes and scientists. I am sure that HeMiBio will result in a vast pool of scientific data that support upcyte® as enabling technology of great value.”


About Medicyte -

Medicyte is specialised in the controlled generation and standardisation of human primary cell products in virtually unlimited quantities and of highest quality for cell therapy and cell- based R&D. Medicytes proprietary technologies upcyte® and vericyte® enable to expand human hepatocytes from different donors and other cells in a standardized way, thereby making these cells for the first time commercially available in high numbers and consistent quality. Increasingly pharmaceutical companies consider using upcyte® hepatocytes for in vitro ADMET testing.

Further information can be found at


Medicyte GmbH

Stefan Holder

Im Neuenheimer Feld 581

69120 Heidelberg

Tel.: +49-6221-72925-30

E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.


This press release reflects only the author’s views.


Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.